Linked Life Data

20716873

Source:http://linkedlifedata.com/resource/pubmed/id/20716873

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-18
pubmed:abstractText
We aimed to elucidate the clinical significance of the expressions of HER2, epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGF-1R), and vascular endothelial growth factor receptor 1, 2, 3 (VEGF-R1, VEGF-R2, and VEGF-R3) in gastric cancer. The study group comprised 57 patients who had undergone gastrectomy at the National Cancer Center Hospital and subsequently received first-line chemotherapy (S-1 monotherapy [n=29] or irinotecan+cisplatin [n=28]) for recurrent or residual tumors. We performed immunohistochemical analysis of formalin-fixed paraffinembedded specimens of surgically removed primary tumors to determine the expressions of HER2, EGFR, IGF-1R, and VEGFR1 in tumor cells and the expressions of VEGF-R1, VEGF-R2, and VEGF-R3 in tumor stromal vessels. The expressions of HER2 (p=0.017) and IGF-1R (p=0.025) were significantly more common in intestinal type tumors than in diffuse type. The protein expressions did not correlate with tumor response in either chemotherapy-regimen group. Among the patients who underwent S-1 monotherapy, those with cytoplasmic VEGF-R1-positive tumors had significantly shorter progression-free survival (logrank, p=0.017). In the survival analysis of all the patients, coexpression of membranous IGF-1R and VEGF-R3 in stromal vessels was the most significant predictor of poor survival (hazard ratio, 1.82; 95% CI, 1.31-2.63; p<0.001). The results of our study will facilitate more efficient use of molecular targeted agents in patients with gastric cancer.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1489-96
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer].
pubmed:affiliation
Chemotherapy Division, National Cancer Center Research Institute.
pubmed:publicationType
Journal Article, English Abstract